BioCentury | Oct 3, 2016
Finance

Dressed in black

...ER, an oral controlled-release formulation of hydrocodone, and insomnia drug Silenor doxepin, a low-dose tricyclic doxepin...
BioCentury | Aug 15, 2016
Company News

Pernix Therapeutics neurology news

...an oral controlled-release formulation of hydrocodone, and insomnia drug Silenor doxepin, a low-dose tricyclic doxepin...
BioCentury | Nov 18, 2013
Analyst Picks & Changes

Analyst picks & changes

...to continued declining prescription trends despite management efforts. The company markets OTC drugs and Silenor doxepin...
...The company lowered its 2013 revenue guidance to $80M from $90-$100M. Rivkind said an OTC Silenor...
BioCentury | Jun 3, 2013
Regulation

Suvorexant safety

...did not request additional preclinical or clinical studies. FDA approved Somaxon Pharmaceuticals Inc. 's Silenor doxepin...
...sleep maintenance data (see BioCentury, March 22, 2010) . Silenor is a low-dose version of doxepin...
BioCentury | May 13, 2013
Company News

Paladin, Pernix Therapeutics sales and marketing update

...Paladin launched Silenor doxepin in Canada for the treatment and symptomatic relief of insomnia characterized by...
...characterized by frequent nocturnal awakening and/or early morning awakenings. Health Canada approved the low-dose tricyclic doxepin...
...Inc. granted Paladin exclusive rights to commercialize the product in Canada, South America and Africa. Silenor...
BioCentury | Feb 18, 2013
Company News

Somaxon, Actavis neurology news

...Somaxon granted Actavis non-exclusive rights to sell a generic version of insomnia drug Silenor doxepin to...
...under certain circumstances which include the U.S. sale of a third party's generic version of Silenor...
...alleging that an ANDA filed by Actavis for generic versions of 3 and 6 mg Silenor...
BioCentury | Dec 24, 2012
Clinical News

Silenor doxepin regulatory update

...Health Canada approved an NDS from Paladin Labs Inc. (TSX:PLB, Montreal, Quebec) for Silenor for the...
...by frequent nocturnal awakening and/or early morning awakenings. Paladin plans to launch the low-dose tricyclic doxepin...
...next quarter (see BioCentury, Dec. 17). Somaxon Pharmaceuticals Inc. (NASDAQ:SOMX), San Diego, Calif. Product: Silenor doxepin...
BioCentury | Dec 17, 2012
Company News

Pernix Therapeutics, Somaxon deal

...The deal gives Pernix rights insomnia drug Silenor doxepin. At Sept. 30, the low-dose tricyclic doxepin...
BioCentury | Jul 23, 2012
Company News

Somaxon, Mylan, Zydus deal

...Somaxon granted Mylan exclusive rights to sell an authorized generic version of insomnia drug Silenor doxepin...
...under its own ANDA. Somaxon also granted Zydus rights to sell a generic version of Silenor...
...co-promotion rights to Silenor in the U.S. Somaxon reported net sales of the low-dose tricyclic doxepin...
BioCentury | Apr 30, 2012
Company News

CJ, Somaxon sales and marketing update

...Somaxon granted CJ CheilJedang Corp. exclusive rights in South Korea to commercialize insomnia therapy Silenor doxepin...
...for sales milestones and royalties. CJ will be responsible for regulatory submissions. The low-dose tricyclic doxepin...
...of the CJ Group. Paladin Labs Inc. (TSX:PLB, Montreal, Quebec) has exclusive rights to commercialize Silenor...
Items per page:
1 - 10 of 139